Rapidly identify CPE carriers and confirm suspected CPE
Covers the clinically most prevalent carbapenemases - KPC, OXA-48, VIM and NDM - including the emerging OXA-181 variant.
- Accurate results in 2 hours directly from rectal swabs or cultures
- Detect KPC, OXA-48, VIM and NDM, including OXA-181
- Enables batch testing
An accurate and rapid method to detect KPC, OXA-48, VIM and NDM genes directly from a rectal screening swab.
- Specimen: Rectal swab
Sample preparation: NucliSENS® easyMAG®
Amplification and detection: ABI 7500, LightCycler® 480 system I & II
- Specimen: Culture
Sample preparation: crude extraction
Amplification and detection: ABI 7500, CFX96TM, LightCycler® 480 system I & II, Rotor-Gene Q
- Carbapenemase target genes*KPC, OXA-48, VIM, NDM
- Controls included
Positive controls: KPC, OXA-48, VIM, NDM
- Limit of detection
< 5 copies/PCR reaction for KPC, OXA-48, VIM and NDM
- Analytical reactivity
• 19 different strains of KPC
• 25 different strains of OXA-48
• 17 different strains of NDM
• 34 different strains of VIM
- Analytical specificity
No positive results when tested against 87 non-carbapenemase producers
*KPC-2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25; OXA-48, 48b, 162, 163, 181, 204, 232, 244, 245, 370; VIM-1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47; NDM-1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16.
Sample preparation - DNA extraction from rectal swabs
- Extract DNA with NucliSENS® easyMAG® using 200 μl rectal swab fluid and 5 μl internal control solution
Sample preparation - DNA extraction from cultures
- Prepare a 0.5 McFarland bacterial cell suspension using PCR-grade water
- Transfer 200 μl cell suspension and 10 μl internal control solution to an Eppendorf tube
- Heat at 98°C for 10 min
- Vortex for 30 seconds
- Spin down for 2 min
Real-time PCR reaction setup
- Prepare the qPCR reaction mix using the CPE PCR Mastermix and CPE solution provided with the kit
- To each well/tube add: 15 μl qPCR reaction mix + 10 μl DNA sample
- Seal plate/close tubes, mix and spin down briefly
- Start the run, using the parameters specified in the user manual
Please refer to the full protocol in the user manual when performing this assay.
Accurate results in 2 hours directly from rectal swabs or cultures
Identify CPE carriers in specific risk groups or confirm CPE in routine suspected isolates. Check-Direct CPE can be performed directly from rectal swabs or culture specimens.
The most clinically prevalent carbapenemases, including OXA-181
Detect the most clinically prevalent carbapenemases, including emerging variants such as OXA-181. Information on the type of carbapenemase present – KPC, OXA-48-like and VIM/NDM – yields extra information for epidemiology.
Enables batch testing
Easily scale up to accommodate for higher testing volumes e.g. when investigating a suspected outbreak. The most common real-time PCR systems are compatible for use with the Check-Direct CPE.
End unnecessary patient isolation sooner
Rapid and accurate results help you end unnecessary patient isolation sooner. Stay up-to-date, stay in control.
Learn more about the technology behind our Check-Direct multiplex real-time PCR products here
- Otter J, Goldenberg S, Walker C, Patel A, Edgeworth J, Ahanonu C, Tosas Auguet O, Querol-Rubiera A, Girdham S, Bisnauthsing K. Universal admission screening for CRE using PCR detects 14-fold more carriers than agar-based methods at a London hospital. Presented at: 25th ECCMID, 25-28 April 2015, Copenhagen, Denmark.
- Eigner U, Veldenzer A, Hefner N, Schwarz R, Holfelder M. Comparison of the Check-Direct CPE real-time PCR kit to selective agar media for the detection of carbapenemases in Enterobacteriaceae. Presented at: 25th ECCMID, 25-28 April 2015, Copenhagen, Denmark.
- Meunier D, Hopkins K, Findlay J, Woodford N. Evaluation of the Check-Direct CPE assay for detecting carbapenemase genes in multidrug-resistant Gram-negative bacteria. Presented at: 25th ECCMID, 25-28 April 2015, Copenhagen, Denmark.
- Eigner U, Veldenzer A, Holfelder M. Validation of the new real-time PCR kit Check-Direct CPE for the detection of KPC, NDM/VIM and OXA-48 in Enterobacteriaceae. Presented at: 66th DGHM, 5-8 October 2014, Dresden, Germany.
- Williams A, Vanstone G, Balakrishnan I. Direct Detection of carbapenemase-producing Enterobacteriaceae and Pseudomonas spp. from positive blood cultures. Presented at: BSAC Spring Meeting; 2014 March 20; London, UK.
- Bullivant J, Smedley C, Davies S, Davis S, Parsons H. Comparison of Check-Point PCR to Multi-Resistant Gram Negative Screening Media for the detection of Carbapenemase Producing Enterobacteriaceae. Presented at: HIS & IPS Spring Meeting; 2014 April 8; Birmingham, UK.
- Nijhuis RHT, Savelkoul PHM, van Zwet AA. Carbapenemase producing bacteria in travellers constitute a potential threat for current hospital infection control programs. Presented at: 24th ECCMID; 2014 May 10-13; Barcelona, Spain.
- Bogaerts P, Delwiche D, Massart M, Huang T-D, Francart H, Verbruggen A-M, Glupczynski Y. Real-Time PCR Assays for the Detection of Carbapenemase-Producing Enterobacteriaceae (CPE) from Stool Samples. Presented at: 53rd ICAAC; 2013 September 12; Denver, CO.
- Huang TD, Bogaerts P, Ghilani E, Heinrichs A, Gavage P, Roisin S, Willems E, Verbruggen AM, Francart H, Denis O, Senterre JM, Glupczynski Y. Multicentre evaluation of the Check-Direct CPE® assay for direct screening of carbapenemase-producing Enterobacteriaceae from rectal swabs. J Antimicrob Chemother. 2015 Jun;70(6):1669-73.
- Findlay J, Hopkins KL, Meunier D, Woodford N. Evaluation of three commercial assays for rapid detection of genes encoding clinically relevant carbapenemases in cultured bacteria. J Antimicrob Chemother. 2015 May;70(5):1338-42.
- Lau AF, Fahle GA, Kemp MA, Jassem AN, Dekker JP, Frank KM. Clinical Performance of Check-Direct CPE, a Multiplex PCR for Direct Detection of blaKPC, blaNDM/VIM, and blaOXA48 from Perirectal Swabs. J Clin Microbiol. 2015 Dec;53(12):3729-37.
- Saegeman V, Van den Eynde J, Niclaes L, De Ridder D, Schuermans A, Glupczynski Y. Performance of different culture methods and of a commercial molecular assay for the detection of carbapenemase-producing Enterobacteriaceae in nursing homes and rehabilitation centers. Eur J Clin Microbiol Infect Dis. Published online ahead of print 2015 Jan 21.
- Nijhuis R, Samuelsen Ø, Savelkoul P, van Zwet A. Evaluation of a new real-time PCR assay (Check-Direct CPE) for rapid detection of KPC, OXA-48, VIM and NDM carbapenemases using spiked rectal swabs. Diagn Microbiol Infect Dis. 2013 Dec;77(4):316-20.
- Österblad M, Lindholm L, Jalava J. Evaluation of two commercial carbapenemase gene assays, the Rapidec Carba NP test and the in-house Rapid Carba NP test, on bacterial cultures. J Antimicrob Chemother. 2016 Mar 31. Published online ahead of print Learn more
|18-0080||Check-Direct CPE kit, 48 reactions*|
|18-0070||4-Color Compensation Set for Check-Direct CPE, for 1 color compensation run**|
Contact your local representative
For information about further supplies needed to run the assay, please refer to the "Materials required but not supplied" section of the respective product's user manual.
*Screening: for ABI 7500, LightCycler® 480 system I & II; Confirmation: for ABI 7500, CFX96TM, LightCycler® 480 system I & II, Rotor-Gene Q.
**for use on the LightCycler® 480 system I & II.
Other Check-Points solutions
EU: For in vitro Diagnostic Use.
US: For Research Use Only. Not for use in diagnostic procedures.
NucliSENS® and easyMAG® are registered trademarks of bioMérieux SA. Applied Biosystems is a registered trademark of Applera Corporation. CFX96TM is a registered trademark of Bio-Rad. LightCycler® is a registered trademark of Roche Diagnostics. Rotor-Gene® is a registered trademark of the QIAGEN group. This product is sold under license from PHRI Properties patent right only for human in vitro diagnostics, food testing, veterinary testing, or research.